Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Omega Clinical Trials LLC

Neither a doctor nor a teaching hospital

Research payments

$9,346,557

289 payments

Through program year 2025, Omega Clinical Trials LLC is reported as receiving $9,346,557 in research payments, across 289 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $5,285,159 70
2024 Research $2,038,434 54
2023 Research $519,537 24
2022 Research $121,138 15
2021 Research $597,361 44
2020 Research $449,704 45
2019 Research $335,223 37

Breakdown

Who paid Research payments · program years 2019–2025
  1. Teva Pharmaceuticals USA, Inc. $6,805,921 187 payments
  2. AbbVie, Inc. $1,790,134 16 payments
  3. Allergan Inc. $688,784 72 payments
  4. Otsuka Pharmaceutical Development & Commercialization, Inc. $23,100 1 payment
  5. ITI, Inc. $20,738 8 payments
  6. ACADIA Pharmaceuticals Inc $14,340 1 payment
  7. Mallinckrodt LLC $2,040 3 payments
  8. Avanir Pharmaceuticals, Inc. $1,500 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study with an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients with Schizophrenia $6,031,523 123 payments
  2. A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (15 mg and 30 mg QD) of?CVL-231?(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis $744,501 2 payments
  3. A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of CVL-231(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis $697,443 6 payments
  4. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia $564,024 48 payments
  5. A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia $265,923 5 payments
  6. A Double-Blind, Placebo-Controlled, Randomized Withdrawal,Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in A Dose-Reduction Paradigm in Theprevention of Relapse in Patients With Schizophrenia $222,938 13 payments
  7. A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia $210,374 16 payments
  8. A Double-Blind, Placebo-Controlled, Randomized Withdrawal,Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in A Dose-Reduction Paradigm in the Prevention of Relapse in Patients With Schizophrenia $161,708 8 payments
  9. A Double-Blind, Placebo-Controlled, Randomized Withdrawal,Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in A Dose-Reduction Paradigm in Theprevention of Relapse in Patients With Schizophrenia $116,535 13 payments
  10. A Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in A Dose-Reduction Paradigm in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current $103,596 19 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record